Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma

MLA

“Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma.” PR Newswire, 25 June 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.798745949&authtype=sso&custid=ns315887.

APA

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma. (2024, June 25). PR Newswire.

Chicago

PR Newswire. 2024. “Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma,” June 25. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.798745949&authtype=sso&custid=ns315887.